Skip to Content Facebook Feature Image

ULTRALUXE 2024 NICHE LUXURY FESTIVAL RETURNS WITH NEW CURATED EXHIBITIONS AND EXPERIENCES

Business

ULTRALUXE 2024 NICHE LUXURY FESTIVAL RETURNS WITH NEW CURATED EXHIBITIONS AND EXPERIENCES
Business

Business

ULTRALUXE 2024 NICHE LUXURY FESTIVAL RETURNS WITH NEW CURATED EXHIBITIONS AND EXPERIENCES

2024-07-15 10:07 Last Updated At:10:25

Be inspired, indulge and invest in the world's first lifestyle social festival

SINGAPORE, July 15, 2024 /PRNewswire/ -- UltraLuxe, Asia's foremost festival of niche luxury, returns to the iconic TENT@Ngee Ann City Civic Plaza, 4–13 October with JeweLuxe, Homme and Advocacy converging over 120 international brands; and new addition of DineLuxe profiling Singapore's culinary talents' iconic gastronomical creations. 

Anchoring the festival is JeweLuxe's 85 independent houses and designers from across the globe in:
Edition 1 (4-8 October) presenting The Protagonist for sustainability, a rarity with Gemagical, the Iconic in Modernissimo, the heritage of Nouveau Asia.
Edition 2 (9–13 October) showcasing Style Inc. jewellery for everyday style, accessible glamour in Glamora and fashion artistry with Nouveau Asia.

Homme is a social space where discerning men explore timepieces, fashion, leisure and wellness. At the core of Homme is UltraBar, designed by Elliot James Interiors to elevate the appreciation of rare and exquisite spirits.

"Our curation of talents and passions locally and around the world will not only present new creative expressions but also indulge connoisseurs with experiences that will inspire their desire to invest in niche luxury for long-term value preservation," says Ms Angela Loh, Founder and CEO, UltraLuxe.

UltraLuxe proudly partners with CIMB as the official sponsor presenting:
The Advocacy panel discussions - a platform where Game Changers, Philanthropists, Tastemakers and advocates of Ageless share their journeys.
The Ultimate Luxescape - an elevated showcase of heritage and iconic jewellery, fashion, timepieces, and culinary curated exclusively for Asia's high-net-worth.

"We are proud to present LuxeScape, an experiential showcase tailored for our affluent Preferred Banking customers. In keeping to its theme of 'purposeful luxury', we are excited to participate in the Advocacy panel discussions on evolving trends and preservation of legacy for the future," says Mr Victor Lee, CEO, CIMB Singapore.

UltraLuxe launches LuxEscapade for those seeking niche travel experiences, preluding with UltraLuxe festival itinerary for international visitors to enjoy red-carpet runway shows, high-profile networking events, and shopping experiences with over 120 international brands.

"The Singapore Tourism Board is delighted to support UltraLuxe as it enriches the diversity and quality of our leisure events pipeline. The festival highlights the unique blend of independent local and international jewellery designers, enhancing the overall retail experience and appeal for locals and visitors worldwide," said Guo Teyi, Director, Retail and Dining, Singapore Tourism Board. 

https://www.ultraluxeglobal.com/ 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

ULTRALUXE 2024 NICHE LUXURY FESTIVAL RETURNS WITH NEW CURATED EXHIBITIONS AND EXPERIENCES

ULTRALUXE 2024 NICHE LUXURY FESTIVAL RETURNS WITH NEW CURATED EXHIBITIONS AND EXPERIENCES

SEOUL, South Korea, Jan. 22, 2025 /PRNewswire/ -- GI Innovation (KQ:358570) announced that it signed a Memorandum of Understanding (MOU) with LaNova Medicines (LaNova) for the development of GI-102 and ADC pancreatic cancer combination therapy.

This MOU was held on January 15th, local time, during JP Morgan Healthcare Conference (San Francisco, USA).

The two companies have been conducting combination therapy study of the immuno-oncology drug GI-102 and ADC LM-302 targeting Claudin18.2 and recently observed excellent anticancer activity in a preclinical pancreatic cancer model.

Both substances are in the clinical stage. GI-102 has completed phase 1 clinical trial in the US and Korea and can quickly enter phase 2. LM-302 is currently in phase 3 clinical trial for 3L and above gastric cancer in China. Pancreatic cancer has no approved immunotherapy, and the only approved treatment is a chemotherapy cocktail, but its treatment efficacy is low and its toxicity is high. Through this agreement, both companies will conduct clinical trial targeting patients with metastatic pancreatic cancer.

Dr. Myoung Ho Jang, CSO said, "We are delighted to be conducting a combination study with LaNova, which is recognized by global pharma companies. LaNova's ADC, which directly destroys tumor cells to increase the response rate, and GI-102, which can enhance immune memory to increase overall survival, are expected to be a combination therapy that can change the pancreatic cancer treatment paradigm."

"GI-102 exemplifies GI Innovation's robust R&D capabilities in immunotherapy. We are excited to explore its combination with LaNova's Claudin18.2 ADC, LM-302, which holds the potential to provide a novel therapeutic option for pancreatic cancer patients" Dr. Crystal Qin, LaNova CEO emphasized.

About GI Inovation

GI Innovation, a KOSDAQ-listed biotech, pioneers fusion protein drugs for cancer and allergies. Since 2017, it secured $230 million through funding rounds, IPO, and licensing deals for preclinical and clinical assets. Leveraging global partnerships for rapid development, the leading programs include immuno-oncology assets GI-101, subcutaneous form GI-102, and anti-allergy asset GI-301, metabolic immuno-oncology asset GI-108 alongside other innovative programs.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

GI Innovation-LaNova Medicines Signs MOU for GI-102 + ADC Pancreatic Cancer Combination Therapy

GI Innovation-LaNova Medicines Signs MOU for GI-102 + ADC Pancreatic Cancer Combination Therapy

Recommended Articles
Hot · Posts